Announcing the initial safety results of the world’s first study of a combination of the AstraZeneca and Sputnik V COVID-19 vaccines, the Russian Direct Investment Fund (RDIF), on Friday said that interim analysis of the data demonstrates a high safety profile for the combined use of the vaccines with no serious adverse events or cases of coronavirus after vaccination. Russia’s sovereign wealth fund on Friday announced initial safety results of the world’s first study of a combination between the COVID-19 vaccine developed jointly with the University of Oxford and the first component of the Russian COVID-19 vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) in the Republic of Azerbaijan. The RDIF was the first in the World to initiate such a study in December 2020. The first partnership of this kind was concluded in December 2020 in the presence of Russian President Vladimir Putin. RDIF, The Gamaleya Center, AstraZeneca and R-Pharm signed a Memorandum of Intent aimed at cooperation in vaccine development.